Physician profile
Ronald Robert Cherry
NPI 1386613511
$1,161.59
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $81.22 · 2021: $213 · 2022: $257 · 2023: $79.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $465.12 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $113.23 | 2019-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.70 | 2022 | |
| Philips North America LLC | $60.38 | 2019-2021 | |
| Allergan, INC. | $50.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.18 | 2019 | |
| Abbvie INC. | $28.02 | 2021 | |
| Mylan Specialty L.P. | $20.16 | 2022 | |
| Tactile Systems Technology INC | $19.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.99 | 2022 | |
| Pfizer INC. | $15.08 | 2019 | |
| Neotract INC. | $15.08 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.63 | 2021 | |
| Merck Sharp & Dohme LLC | $12.21 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.